Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
August 22, 2023
Assignees:
INSTITUTO MASSONE S.A., Raäl Enrique Massone
Inventors:
Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band, Elena M. V. de Cavanagh
Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
Type:
Grant
Filed:
July 7, 2016
Date of Patent:
November 9, 2021
Assignees:
INSTITUTO MASSONE S.A.
Inventors:
Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band, Elena M. V. de Cavanagh
Abstract: The present invention refers to a method of purification of HMG (human menopausal gonadotropin) by multimodal chromatography in order to obtain HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition.
Type:
Grant
Filed:
May 21, 2015
Date of Patent:
March 20, 2018
Assignees:
INSTITUTO MASSONE S.A., RAUL ENRIQUE MASSONE
Inventors:
Liliana Balanián, Mariana Cancela, Claudio Wolfenson, José Groisman
Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
Type:
Application
Filed:
February 8, 2013
Publication date:
January 1, 2015
Applicant:
Instituto Massone S.A.
Inventors:
Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band
Abstract: Purification process of humanPurification process of human urinary gonadotropins of high biological activity and chemical purity absolutely free of foreign contaminating materials derived from the use of biological reagents or chromatography dyes, from crude of gonadotropins. The high biological activity and chemically pure composition of human gonadotropins obtained by this process, are used for the treatment of infertility and are selected from the group of follitropin or menotropins, having a bioactivity greater than 2500 IU/mg protein as tested by biological assay in rats, for both FSH and LH hormones for menotropins and greater than 5000 IU/mg protein for follitropin having an FSH:LH ratio about 75:1. Pharmaceutical preparations of said gonadotropins free of these contaminating materials are also comprised within the present invention.
Type:
Grant
Filed:
April 14, 2000
Date of Patent:
April 4, 2006
Assignee:
Instituto Massone S.A.
Inventors:
Claudio Fernando Wolfenson Band, Liliana Ester Balanian, Jose-Felipe Groisman, Erundina Marta Fasanella